Cilengitide treatment for malignant glioma

Current status and future direction

Kazuhiko Kurozumi, Tomotsugu Ichikawa, Manabu Onishi, Kentaro Fujii, Isao Date

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Malignant glioma is the most common primary brain tumor and accounts for the majority of diagnoses. Treatment has involved a combination of surgery, radiation, and chemotherapy, yet these modalities rarely extend the life of the patient to more than one year from diagnosis. Integrins are expressed in tumor cells and tumor endothelial cells, and are important in angiogenesis and invasion in glioma. αvβ3 and αvβ5 integrins regulate cell adhesion, and inhibitors of these integrins suppress tumor growth in certain pre-clinical models. Several integrin-targeted drugs are in clinical trials as potential compounds for the treatment of cancer. Among them, cilengitide is a novel integrin antagonist for the treatment of glioblastoma. The multimodal anti-glioma effects are based on its cytotoxic, anti-angiogenic, anti-invasive, and synergetic effects. Preclinical studies showed a promising synergy between cilengitide and radiochemotherapy in order to normalize tumor vasculature and attenuate tumor invasion. Cilengitide is currently being assessed in phase III trials for patients with glioblastoma multiforme and in phase II trials for other types of cancers, demonstrating promising therapeutic outcomes to date. The results of these and other clinical studies are expected with great hope and interest. A more clear understanding of the benefits and pitfalls of each approach can then lead to the design of strategies to derive maximal benefit from these therapies.

Original languageEnglish
Pages (from-to)539-547
Number of pages9
JournalNeurologia Medico-Chirurgica
Volume52
Issue number8
DOIs
Publication statusPublished - 2012

Fingerprint

Glioma
Integrins
Neoplasms
Glioblastoma
Therapeutics
Chemoradiotherapy
Cilengitide
Direction compound
Cell Adhesion
Brain Neoplasms
Endothelial Cells
Clinical Trials
Radiation
Drug Therapy
Growth
Pharmaceutical Preparations

Keywords

  • Angiogenesis
  • Cilengitide
  • Integrin
  • Invasion
  • Malignant glioma

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Cilengitide treatment for malignant glioma : Current status and future direction. / Kurozumi, Kazuhiko; Ichikawa, Tomotsugu; Onishi, Manabu; Fujii, Kentaro; Date, Isao.

In: Neurologia Medico-Chirurgica, Vol. 52, No. 8, 2012, p. 539-547.

Research output: Contribution to journalArticle

@article{94df65f87f284644bfd36216721c8076,
title = "Cilengitide treatment for malignant glioma: Current status and future direction",
abstract = "Malignant glioma is the most common primary brain tumor and accounts for the majority of diagnoses. Treatment has involved a combination of surgery, radiation, and chemotherapy, yet these modalities rarely extend the life of the patient to more than one year from diagnosis. Integrins are expressed in tumor cells and tumor endothelial cells, and are important in angiogenesis and invasion in glioma. αvβ3 and αvβ5 integrins regulate cell adhesion, and inhibitors of these integrins suppress tumor growth in certain pre-clinical models. Several integrin-targeted drugs are in clinical trials as potential compounds for the treatment of cancer. Among them, cilengitide is a novel integrin antagonist for the treatment of glioblastoma. The multimodal anti-glioma effects are based on its cytotoxic, anti-angiogenic, anti-invasive, and synergetic effects. Preclinical studies showed a promising synergy between cilengitide and radiochemotherapy in order to normalize tumor vasculature and attenuate tumor invasion. Cilengitide is currently being assessed in phase III trials for patients with glioblastoma multiforme and in phase II trials for other types of cancers, demonstrating promising therapeutic outcomes to date. The results of these and other clinical studies are expected with great hope and interest. A more clear understanding of the benefits and pitfalls of each approach can then lead to the design of strategies to derive maximal benefit from these therapies.",
keywords = "Angiogenesis, Cilengitide, Integrin, Invasion, Malignant glioma",
author = "Kazuhiko Kurozumi and Tomotsugu Ichikawa and Manabu Onishi and Kentaro Fujii and Isao Date",
year = "2012",
doi = "10.2176/nmc.52.539",
language = "English",
volume = "52",
pages = "539--547",
journal = "Neurologia Medico-Chirurgica",
issn = "0470-8105",
publisher = "Japan Neurosurgical Society",
number = "8",

}

TY - JOUR

T1 - Cilengitide treatment for malignant glioma

T2 - Current status and future direction

AU - Kurozumi, Kazuhiko

AU - Ichikawa, Tomotsugu

AU - Onishi, Manabu

AU - Fujii, Kentaro

AU - Date, Isao

PY - 2012

Y1 - 2012

N2 - Malignant glioma is the most common primary brain tumor and accounts for the majority of diagnoses. Treatment has involved a combination of surgery, radiation, and chemotherapy, yet these modalities rarely extend the life of the patient to more than one year from diagnosis. Integrins are expressed in tumor cells and tumor endothelial cells, and are important in angiogenesis and invasion in glioma. αvβ3 and αvβ5 integrins regulate cell adhesion, and inhibitors of these integrins suppress tumor growth in certain pre-clinical models. Several integrin-targeted drugs are in clinical trials as potential compounds for the treatment of cancer. Among them, cilengitide is a novel integrin antagonist for the treatment of glioblastoma. The multimodal anti-glioma effects are based on its cytotoxic, anti-angiogenic, anti-invasive, and synergetic effects. Preclinical studies showed a promising synergy between cilengitide and radiochemotherapy in order to normalize tumor vasculature and attenuate tumor invasion. Cilengitide is currently being assessed in phase III trials for patients with glioblastoma multiforme and in phase II trials for other types of cancers, demonstrating promising therapeutic outcomes to date. The results of these and other clinical studies are expected with great hope and interest. A more clear understanding of the benefits and pitfalls of each approach can then lead to the design of strategies to derive maximal benefit from these therapies.

AB - Malignant glioma is the most common primary brain tumor and accounts for the majority of diagnoses. Treatment has involved a combination of surgery, radiation, and chemotherapy, yet these modalities rarely extend the life of the patient to more than one year from diagnosis. Integrins are expressed in tumor cells and tumor endothelial cells, and are important in angiogenesis and invasion in glioma. αvβ3 and αvβ5 integrins regulate cell adhesion, and inhibitors of these integrins suppress tumor growth in certain pre-clinical models. Several integrin-targeted drugs are in clinical trials as potential compounds for the treatment of cancer. Among them, cilengitide is a novel integrin antagonist for the treatment of glioblastoma. The multimodal anti-glioma effects are based on its cytotoxic, anti-angiogenic, anti-invasive, and synergetic effects. Preclinical studies showed a promising synergy between cilengitide and radiochemotherapy in order to normalize tumor vasculature and attenuate tumor invasion. Cilengitide is currently being assessed in phase III trials for patients with glioblastoma multiforme and in phase II trials for other types of cancers, demonstrating promising therapeutic outcomes to date. The results of these and other clinical studies are expected with great hope and interest. A more clear understanding of the benefits and pitfalls of each approach can then lead to the design of strategies to derive maximal benefit from these therapies.

KW - Angiogenesis

KW - Cilengitide

KW - Integrin

KW - Invasion

KW - Malignant glioma

UR - http://www.scopus.com/inward/record.url?scp=84865522116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865522116&partnerID=8YFLogxK

U2 - 10.2176/nmc.52.539

DO - 10.2176/nmc.52.539

M3 - Article

VL - 52

SP - 539

EP - 547

JO - Neurologia Medico-Chirurgica

JF - Neurologia Medico-Chirurgica

SN - 0470-8105

IS - 8

ER -